Cargando…

Clinical Manifestations of Human Exposure to Fungi

Biological particles, along with inorganic gaseous and particulate pollutants, constitute an ever-present component of the atmosphere and surfaces. Among these particles are fungal species colonizing almost all ecosystems, including the human body. Although inoffensive to most people, fungi can be r...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Manuela, Oliveira, Diana, Lisboa, Carmen, Boechat, José Laerte, Delgado, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052331/
https://www.ncbi.nlm.nih.gov/pubmed/36983549
http://dx.doi.org/10.3390/jof9030381
_version_ 1785015135844171776
author Oliveira, Manuela
Oliveira, Diana
Lisboa, Carmen
Boechat, José Laerte
Delgado, Luís
author_facet Oliveira, Manuela
Oliveira, Diana
Lisboa, Carmen
Boechat, José Laerte
Delgado, Luís
author_sort Oliveira, Manuela
collection PubMed
description Biological particles, along with inorganic gaseous and particulate pollutants, constitute an ever-present component of the atmosphere and surfaces. Among these particles are fungal species colonizing almost all ecosystems, including the human body. Although inoffensive to most people, fungi can be responsible for several health problems, such as allergic fungal diseases and fungal infections. Worldwide fungal disease incidence is increasing, with new emerging fungal diseases appearing yearly. Reasons for this increase are the expansion of life expectancy, the number of immunocompromised patients (immunosuppressive treatments for transplantation, autoimmune diseases, and immunodeficiency diseases), the number of uncontrolled underlying conditions (e.g., diabetes mellitus), and the misusage of medication (e.g., corticosteroids and broad-spectrum antibiotics). Managing fungal diseases is challenging; only four classes of antifungal drugs are available, resistance to these drugs is increasing, and no vaccines have been approved. The present work reviews the implications of fungal particles in human health from allergic diseases (i.e., allergic bronchopulmonary aspergillosis, severe asthma with fungal sensitization, thunderstorm asthma, allergic fungal rhinosinusitis, and occupational lung diseases) to infections (i.e., superficial, subcutaneous, and systemic infections). Topics such as the etiological agent, risk factors, clinical manifestations, diagnosis, and treatment will be revised to improve the knowledge of this growing health concern.
format Online
Article
Text
id pubmed-10052331
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100523312023-03-30 Clinical Manifestations of Human Exposure to Fungi Oliveira, Manuela Oliveira, Diana Lisboa, Carmen Boechat, José Laerte Delgado, Luís J Fungi (Basel) Review Biological particles, along with inorganic gaseous and particulate pollutants, constitute an ever-present component of the atmosphere and surfaces. Among these particles are fungal species colonizing almost all ecosystems, including the human body. Although inoffensive to most people, fungi can be responsible for several health problems, such as allergic fungal diseases and fungal infections. Worldwide fungal disease incidence is increasing, with new emerging fungal diseases appearing yearly. Reasons for this increase are the expansion of life expectancy, the number of immunocompromised patients (immunosuppressive treatments for transplantation, autoimmune diseases, and immunodeficiency diseases), the number of uncontrolled underlying conditions (e.g., diabetes mellitus), and the misusage of medication (e.g., corticosteroids and broad-spectrum antibiotics). Managing fungal diseases is challenging; only four classes of antifungal drugs are available, resistance to these drugs is increasing, and no vaccines have been approved. The present work reviews the implications of fungal particles in human health from allergic diseases (i.e., allergic bronchopulmonary aspergillosis, severe asthma with fungal sensitization, thunderstorm asthma, allergic fungal rhinosinusitis, and occupational lung diseases) to infections (i.e., superficial, subcutaneous, and systemic infections). Topics such as the etiological agent, risk factors, clinical manifestations, diagnosis, and treatment will be revised to improve the knowledge of this growing health concern. MDPI 2023-03-21 /pmc/articles/PMC10052331/ /pubmed/36983549 http://dx.doi.org/10.3390/jof9030381 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Oliveira, Manuela
Oliveira, Diana
Lisboa, Carmen
Boechat, José Laerte
Delgado, Luís
Clinical Manifestations of Human Exposure to Fungi
title Clinical Manifestations of Human Exposure to Fungi
title_full Clinical Manifestations of Human Exposure to Fungi
title_fullStr Clinical Manifestations of Human Exposure to Fungi
title_full_unstemmed Clinical Manifestations of Human Exposure to Fungi
title_short Clinical Manifestations of Human Exposure to Fungi
title_sort clinical manifestations of human exposure to fungi
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052331/
https://www.ncbi.nlm.nih.gov/pubmed/36983549
http://dx.doi.org/10.3390/jof9030381
work_keys_str_mv AT oliveiramanuela clinicalmanifestationsofhumanexposuretofungi
AT oliveiradiana clinicalmanifestationsofhumanexposuretofungi
AT lisboacarmen clinicalmanifestationsofhumanexposuretofungi
AT boechatjoselaerte clinicalmanifestationsofhumanexposuretofungi
AT delgadoluis clinicalmanifestationsofhumanexposuretofungi